Structure-Based Computational Screening of Indonesian Spice-Derived Compounds Targeting the Neuropeptide Y1 Receptor

Read full text Summarise with VIRAT
Authors: Blessari Tesalonika Woran, Jessica Angelina Jollie, Michael Nathanael Dharmasetiawan, Kevin Purwadinata Kusnadi
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The neuropeptide Y1 receptor (NPY1R) is a promising therapeutic target for type 2 diabetes mellitus (T2DM) due to its role in regulating appetite and insulin secretion. Indonesian spices contain diverse bioactive compounds with potential metabolic effects, yet their interaction with NPY1R remains largely unexplored. This study aimed to identify potential natural allosteric modulators of NPY1R using structure-based virtual screening and pharmacokinetic analysis. A total of 17,356 compounds from the NCBI PubChem database were pre-filtered, yielding 860 ligands for blind molecular docking. Of these, 97 showed stronger predicted binding affinities than the reference antagonist BMS-193885. Further screening based on physicochemical properties, toxicity, and ADMET parameters identified six top candidates. Among them, cis-theaspirone demonstrated the most favorable profile, including binding to an allosteric pocket (–10.0 kcal/mol; RMSD 2.658 Å), high gastrointestinal absorption, blood–brain barrier permeability, and acceptable solubility. Molecular dynamics simulations over 50 ns confirmed stable ligand–receptor interactions. Overall, cis-theaspirone emerges as a potential NPY1R modulator, highlighting the promise of Indonesian spice-derived compounds for further investigation in metabolic disease research.

Fields of Study & Subjects

Computational Drug Discovery Methods Bioactive natural compounds Receptor Mechanisms and Signaling

Publication details

Journal / source
Indonesian Journal of Life Sciences
Pages
21–40
Publication date
31 March 2026
Language
EN